FIELD: biochemistry.
SUBSTANCE: invention refers to using an antibody containing a human IgG Fc region and two antigen-binding domains to eliminate plasma antigens. Also disclosed is a method of screening an antibody having a function of eliminating an antigen from plasma, involving contacting the antigen with an antigen-binding domain at pH 5.8 and pH 7.4 respectively, obtaining an antigen-binding domain whose antigen-binding activity varies depending on pH conditions and has a KD (pH 5.8)/KD (pH 7.4) value, defined as the KD ratio for the given antigen at pH 5.8 and KD for the given antigen at pH 7.4, equal to 2 or more. Invention also relates to a method of producing an antibody having a function of eliminating an antigen from plasma, comprising obtaining an antigen-binding domain, whose antigen-binding activity varies depending on the pH conditions, and has a KD (pH 5.8)/KD (pH 7.4) value, defined as the KD ratio for the given antigen at pH 5.8 and KD for the given antigen at pH 7.4, equal to 2 or more.
EFFECT: invention enables to efficiently produce an antibody possessing the antigen elimination function.
23 cl, 27 dwg, 16 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FcγRIIB | 2013 |
|
RU2812226C1 |
ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FCΓRIIB | 2013 |
|
RU2736349C2 |
ANTIGEN-BINDING MOLECULE SPECIFIC TO TARGET TISSUE | 2013 |
|
RU2743463C2 |
ANTIGEN-BINDING MOLECULE CAPABLE OF MULTIPLE BINDING TO A VARIETY OF ANTIGEN MOLECULES | 2018 |
|
RU2757786C2 |
Fc-REGION OPTION | 2014 |
|
RU2757124C2 |
IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
Authors
Dates
2020-12-28—Published
2012-11-30—Filed